IRIS
ROTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.375
EU - Europa 2.152
AS - Asia 1.056
AF - Africa 30
OC - Oceania 4
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.621
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.354
CN - Cina 671
IT - Italia 552
IE - Irlanda 485
SE - Svezia 353
SG - Singapore 255
DE - Germania 191
FI - Finlandia 144
UA - Ucraina 138
TR - Turchia 80
AT - Austria 79
FR - Francia 71
GB - Regno Unito 37
IN - India 33
CI - Costa d'Avorio 29
NL - Olanda 27
BE - Belgio 18
CA - Canada 18
CZ - Repubblica Ceca 14
RU - Federazione Russa 11
JP - Giappone 7
IR - Iran 6
RO - Romania 5
AU - Australia 4
LU - Lussemburgo 4
CH - Svizzera 3
HU - Ungheria 3
PA - Panama 3
BG - Bulgaria 2
BR - Brasile 2
ES - Italia 2
GR - Grecia 2
HK - Hong Kong 2
MD - Moldavia 2
PL - Polonia 2
RS - Serbia 2
AL - Albania 1
BH - Bahrain 1
BO - Bolivia 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
HR - Croazia 1
LT - Lituania 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.621
Salva come PNG Salva come JPEG
Città #
Dublin 485
Chandler 472
Ashburn 231
Boardman 187
Singapore 183
Parma 161
Jacksonville 135
Beijing 131
Ann Arbor 126
Dearborn 105
Princeton 90
Nanjing 84
Shanghai 76
Vienna 72
Izmir 71
Wilmington 62
Grafing 53
San Mateo 50
Shenyang 49
Marseille 48
Helsinki 44
Jinan 44
Nanchang 41
New York 36
Bologna 35
Hebei 32
Abidjan 29
Milan 28
Seattle 26
Santa Clara 24
Changsha 20
Des Moines 20
Hefei 20
Kunming 20
Verona 20
Guangzhou 19
Tianjin 19
Amsterdam 18
Bremen 17
Los Angeles 17
Pune 17
Fremont 16
Jiaxing 16
Toronto 16
Brussels 15
West Jordan 14
Dallas 13
Norwalk 13
Perugia 13
Brno 12
Chicago 11
Rome 11
Woodbridge 11
Hangzhou 10
Houston 10
Munich 10
Carpi 9
Düsseldorf 9
Haikou 9
Modena 9
Trento 9
Zhengzhou 9
Kocaeli 8
Auburn Hills 7
Ningbo 7
Reggio Emilia 6
Bolzano 5
Florence 5
Lanzhou 5
Mestre 5
Trieste 5
Turin 5
Assago 4
Augusta 4
Boretto 4
Cordovado 4
Fairfield 4
Leipzig 4
London 4
Magdeburg 4
Neviano degli Arduini 4
Redwood City 4
Rockville 4
Rovereto 4
Arezzo 3
Brescia 3
Budapest 3
Camerino 3
Chengdu 3
Falls Church 3
Fidenza 3
Kolkata 3
Kyiv 3
Kyoto 3
Licata 3
Melbourne 3
Orzinuovi 3
Piacenza 3
Redmond 3
Rho 3
Totale 3.816
Salva come PNG Salva come JPEG
Nome #
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 117
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 115
Targeting oncogenic Notch signaling with SERCA inhibitors 109
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia 97
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 94
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 92
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 91
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 88
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 88
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 85
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 84
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 83
Angiopoietins expression by human myeloma cells 82
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis 79
IL-7 is produced by myeloma cells in presence of IL-6 77
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 77
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 76
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 75
Multiple myeloma patient with unusual extramedullary involvement 74
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 73
Osteopontin is produced by human multiple myeloma cells 73
Acute lymphoblastic leukaemia in Noonan syndrome. 73
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 73
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 72
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 71
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 70
Multiple Myeloma patient with unusual extramedullary involvement 69
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 67
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 67
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 65
Multiple myeloma patient with unusual extramedullary involvement 65
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 65
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 65
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 64
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 63
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 62
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 62
Activating somatic and germline TERT promoter variants in myeloid malignancies 62
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia 62
IL-7 is produced by myeloma cells in presence of IL-6 59
Genetic and proteomic approaches to identify cancer drug targets. 58
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 58
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia 58
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 57
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 56
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 55
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling 55
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 54
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 54
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 52
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 52
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells 51
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia 50
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 49
Leukemia-specific delivery of mutant NOT CH1 targeted therapy 49
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia 49
Targeting Notch Trafficking and Processing in Cancers 49
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 49
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 49
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 49
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 48
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES 47
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 44
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. 43
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 43
Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia 42
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro 41
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 41
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes 41
227P Sexual dimorphism in immune profile of early and advanced NSCLC 40
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 40
WO/2016/073708 40
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 38
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. 38
DHPLC analysis of NPM1 mutations in adult primary AML. 38
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 38
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 37
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma 37
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 36
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E 34
Genetic pathways in low-and high-grade HCV-related lymphomas are different 33
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. 33
Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL 33
Mutational analisys of JAK2 VAL617PHE in a new series of chronic myelomonocytic leukemia and related atypical myeloproliferative disorders 33
Modulating Notch1 With Signature-based Small Molecule Library Screening 32
The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies 32
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights 32
Targeting NOTCH1 in hematopoietic malignancy. 31
Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in Acute Myeloid Leukemia 31
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement 30
NPM1 haploinsufficiency in MDS/AML with del(5q)/monosomy 5 29
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 28
SERCA MODULATION COUNTERACTS GLUCOCORTICOID RESISTANCE IN T-ALL 26
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia 26
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 26
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis 25
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy 25
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 24
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 22
Identification of AML1-ETO modulators by chemical genomics. 22
Totale 5.517
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020494 0 0 0 18 58 83 64 19 35 133 38 46
2020/2021515 16 33 38 20 56 17 34 23 128 47 78 25
2021/2022517 16 16 11 15 7 64 72 55 27 40 32 162
2022/20231.922 219 191 106 124 206 206 32 117 585 7 82 47
2023/2024987 50 64 29 41 85 184 124 80 40 72 72 146
2024/2025584 90 164 215 115 0 0 0 0 0 0 0 0
Totale 5.771